NCT02670772 - Dose Optimisation of Stavudine for the Treatment of HIV Infection | Biotech Hunter

Enrollment

1,077

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2015

Conditions

Acquired Immune Deficiency SyndromeHuman Immunodeficiency Virus

Interventions

DRUG

Stavudine

Stavudine 20mg twice daily for 96 weeks + Placebo 300mg once daily for 96 weeks + Lamivudine 150mg twice daily for 96 weeks + Efavirenz 600mg once daily for 96 weeks

DRUG

Tenofovir Disoproxil Fumarate

TDF 300mg once daily + Placebo 20mg twice daily for 96 weeks + Lamivudine 150mg twice daily for 96 weeks + Efavirenz 600mg once daily for 96 weeks

Trial Locations (3)

2196

Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg

25641

The Infectious Disease Institute (IDI), Mulago Hospital Complex, Kampala

600113

VHS-YRG Care Medical Centre, Chennai

All Listed Sponsors

collaborator

Bill and Melinda Gates Foundation

OTHER

lead

Willem Daniel Francois Venter

OTHER